Gastroenterology

Investigators compared 2 groups, before and after the initiation of a biosimilar program at their hospital.

Relapses occurred in only 4 of 14 patients treated with the combination of Metronidazole with Vancomycin.

These findings suggest a potential in developing preventative vaccines against C. difficile infection.

In data presented at UEG, investigators find post-dupilumab transcriptome closely resembles the transcriptome of a healthy control group.

New data shows that clinical isolates of C. difficile are variably affected by manuka honey in terms of growth inhibition and bactericidal activity.

Only 29.5% of sampled CBD users claimed any wellness benefit.

The longitudinal study included 209 children, one of the largest samples in the world for a study on this topic.

The absolute SCr criterion correlated better with all-cause mortality than the relative increase in serum creatinine.

The study observed 50 women taking infliximab, adalimumab, and vedolizumab.

New cohort analysis shows patients with ulcerative colitis or Crohn's disease who have received invasive care may be affected long-term.

NASH and NAFLD are notoriously difficult to treat conditions.

TLR9 activation shows potential as a target for ulcerative colitis and warrants further testing.

These findings underline the importance of aggressive management to treat IBD and ACS comorbidities to improve outcomes.

Dr. Moon says new strategies must be implemented to help NAFLD patients deal with pain.

This edition from the 10 Year Plan features perspective from leadership at WGO and Crohn's & Colitis Foundation, as well as survey results from gastroenterologists.

As part of the TARGET-NASH study, researchers find 18% of NAFLD patients are prescribed opioids because of pain.

This article is the final installment of four articles exploring the epidemic of liver disease called nonalcoholic fatty liver disease and its more severe form, nonalcoholic steatohepatitis.

Testing all IBD patients for CMV can lead to a concerning overconsumption of resources as well as a delay in treatment.

The trial was called off because of futility of the toxoid vaccine candidate.

The cut points for LCT and nCD64 in Crohn’s disease were not previously known.

Fecal material transplantation for the management of patients with IBD demonstrates a response rate of 53.8% with a complete remission of 37%.

This article is the third in a series of four articles exploring the epidemic of liver disease called nonalcoholic fatty liver disease and its more severe form, nonalcoholic steatohepatitis.

Ustekinumab should be prescribed cautiously to those at high cardiovascular risk.

Low levels of COC associated with a higher likelihood of outpatient flares that required corticosteroids, hospitalizations, and surgical interventions.

There are currently no FDA-approved treatments for eosinophilic esophagitis.

This article is the second in a series of four articles exploring the epidemic of liver disease called nonalcoholic fatty liver disease and its more severe form, nonalcoholic steatohepatitis.

This article is the first in a series of 4 articles exploring the epidemic of liver disease called nonalcoholic fatty liver disease and its more severe form, nonalcoholic steatohepatitis.

In a poster presented at ERS, researchers find the complement and coagulation cascades pathway was up-regulated in response to airway presence of Moraxella genera that might suggest an activation of systemic innate immunity in response to Moraxella.

There was no differences found between liver transplant patients and a control group on the proportion of hospitalized patients and patients who required intensive care.

No life-threatening adverse events occurred in the 150 patient trial to treat non-alcoholic fatty liver disease.